With the anticipated expiry of patent protection for semaglutide , the active molecule behind widely used anti-diabetic and anti-obesity medications, the Indian pharmaceutical landscape is poised for a major transformation
Those who are overweight and obese, as well as those who have failed with other conventional weight loss drugs, might need it
This statute states it is not an act of infringement to make, use, or sell a patented invention solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs
Vijay apart from his contemporaries is his commitment to communication and openness with his patients
Retatrutide's Regulatory Status in the UK Retatrutide has not received MHRA or EMA marketing authorisation as of mid-2025 and is not available through NHS prescribing
Retatrutide might